Table 3. Medications prescribed to men and women CVD patients.
- = not reported. % refers to the percentage of male and then female participants separately. *significant male-to-female difference p = <0.001
Specified antihypertensive medicines in Lee et al.'s [47] study include short-acting nitrates, angiotensin-converting enzyme inhibitors (ACEIs), and angiotensin receptor blockers (ARB). Specified antihypertensive medicines in Mariani et al.'s [36] study include ARB, ACEIs, and calcium channel blockers (CCB). Millett et al. [37] reported antianginal: nitrate (in men 9.8 and women 12.4%). The study by Verani et al. [41] reported statins and high-intensity statins. Antihypertensive medicines reported by Zhao et al. [43] include total antihypertensive, ACE, ARB, and CCB. Zhao et al. [43] reported antianginal nitrates (30.5% in men and 37% in women). Statins reported in Rachamin et al.'s [51] study include low intensity, medium intensity, and high intensity (as primary and secondary prevention of CVDs); the antihypertensive medicines reported were ARB and CCB as primary and secondary prevention of CVDs, respectively.
| Study | Prescribed Medication(s) | ||||||||||||||||||||
| Antiplatelet (%) | Aspirin (%) | Lipid-lowering agents (%) | Statin (%) | β-Blocker (%) | Oral anticoagulant | Antihypertensive | |||||||||||||||
| Men | Women | Men | Women | Men | Women | Men | Women | Men | Women | Men | Women | Men | Women | ||||||||
| Daly et al., 2006 [44] | 84* | 76* | 81* | 73* | 53* | 47* | 51* | 45* | 67 | 65 | - | - | - | - | |||||||
| Hyun et al., 2017 [45] | 57.4* | 53.4* | 7.9 | 7.6 | 69.1 | 67.5 | 69.1 | 67.5 | 78.1* | 80.2* | 7.9 | 7.6 | 78.1 | 80.2 | |||||||
| Lee et al., 2019 [47] | 46.02* | 32.08* | 46.02* | 32.08* | - | - | 79.4* | 61.2* | 52.3* | 41.1* | - | - | 34.8 | 30.1 | |||||||
| Leening et al., 2018 [34] | - | - | - | - | - | - | 8.2 | 9.9 | 22 | 26.5 | - | - | 22 | 26.5 | |||||||
| Mariani et al., 2013 [36] | 71.9 | 64.6 | 95.1 | 94.3 | - | - | 89.6* | 84.7* | 86.8* | 81.2* | - | - | 9.8 | 12.4 | |||||||
| Millett et al., 2018 [37] | - | - | - | - | 14.2 | 8.8 | - | - | - | - | - | - | 15.6 | 12.3 | |||||||
| Nørgaard et al., 2015 [39] | - | - | - | - | 35.9 | 32.3 | - | - | - | - | - | - | 37.7 | 40 | |||||||
| Peters et al., 2018 [40] | 61.7* | 54.5* | - | - | 10.7* | 9.2* | 14* | 12* | 81.2 | 79.5 | - | - | - | - | |||||||
| Rachamin et al., 2021 [51] | - | - | - | - | - | - | 1/1.7 | 1.3/3.4 | 18.9/61.3 | 19.9/56.8 | - | - | 50.5/12.7 | 54.4/12.3 | |||||||
| Virani et al., 2015 [41] | - | - | - | - | - | - | 64.8 | 57.6 | - | - | - | - | - | - | |||||||
| Zhao et al., 2017 [43] | 91.7 | 86.3 | 92.2 | 92.1 | - | - | 83.5 | 75.7 | 73 | 68.4 | - | - | 92.2 | 92.1 | |||||||